Idorsia Ltd

IDIA

Equity

ISIN CH0363463438 / Valor 36346343

SIX Swiss Exchange (2026-02-20)

CHF 3.69-4.40%

Idorsia Ltd
UMushroom community rating:

4.46 11 votes No rating yet

NegativeNeutralPositive

About company

Idorsia Ltd is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company aims to address significant unmet medical needs by advancing a diverse pipeline of drug candidates across various therapeutic areas. Idorsia's research and development efforts are concentrated on creating novel treatments that can improve patient outcomes. With a commitment to scientific excellence, the company leverages its expertise in drug discovery and development to bring new therapies to market. Headquartered in Switzerland, Idorsia operates with a global perspective, seeking to make a meaningful impact on healthcare through its innovative pharmaceutical solutions.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

328%1Y

-68.6%3Y

-85.2%5Y

Performance

78.3%1Y

99.5%3Y

81.5%5Y

Volatility

1109 M

Market cap (USD)

1,022,450

Daily traded volume (Shares)

0.849 / 0.78

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.46

11 votes

Performance:

4.08

Innovation:

4.69

Society:

4.38

Nature:

4.15

Theo Clausen

Switzerland, 16 Oct 2025

In the last days an important capital increase has been done by Idorisa to have avaible cash to sell there medicaments. I see long term return in profitabilty for the company.